The observation that alternative splice variants of Osteopontin may be produced selectively in cancer, and that distinct types of cancer may express different combinations of spice variants has opened the field for a more refined evaluation of the potential for utilizing Osteopontin forms in cancer detection, assessment of aggressiveness, prognostication, or prediction of treatment responses. Here, SPP1 is linked to cancer.